Related Experiment Video

Updated: Aug 18, 2026

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

Potential role of ubiquinone (coenzyme Q10) in pediatric cardiomyopathy

Hemmi N Bhagavan1, Raj K Chopra

  • 1Nutrition Science Department, Tishcon Corporation, 30 New York Avenue, P.O. Box 331, Westbury, NY 11590, USA. hemmin@msn.com

Clinical Nutrition (Edinburgh, Scotland)
|May 18, 2005
PubMed

Insights

Pediatric cardiomyopathy (PCM) is a rare, life-threatening condition. Coenzyme Q10 shows promise as a supportive therapy for children with PCM, particularly those with dilated cardiomyopathy, though more research is needed.

Area of Science:

  • Cardiology
  • Pediatric Medicine
  • Biochemistry

Background:

  • Pediatric cardiomyopathy (PCM) is a rare and severe group of heart muscle disorders in children.
  • PCM has a high mortality rate, with 40% of symptomatic children facing heart transplant or death within two years.
  • Despite advances, survival rates for PCM have not improved significantly over the last 35 years.

Purpose of the Study:

  • To explore the potential role of Coenzyme Q10 (CoQ10) as a therapeutic agent in pediatric cardiomyopathy.
  • To investigate CoQ10's biochemical rationale, including its role in mitochondrial function and antioxidant properties, for PCM treatment.

Main Methods:

  • Review of existing literature on adult cardiomyopathy, heart failure, and mitochondrial diseases with cardiac involvement.
  • Analysis of biochemical data supporting CoQ10's function in energy production and antioxidant activity.
  • Assessment of preliminary findings suggesting CoQ10's efficacy in PCM.

Main Results:

  • Coenzyme Q10 plays a crucial role in mitochondrial energy production (ATP synthesis) and acts as an antioxidant.
  • Existing data from adult cardiomyopathy and related conditions suggest a potential benefit of CoQ10 therapy.
  • Preliminary results indicate promising outcomes for CoQ10 use in PCM patients.

Conclusions:

  • A biochemical rationale supports the use of Coenzyme Q10 in pediatric cardiomyopathy.
  • CoQ10 supplementation may be a valuable adjunct to conventional therapies for PCM.
  • Further studies are warranted to confirm the efficacy of CoQ10, especially in children with dilated cardiomyopathy.

More Related Videos

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools05:27

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools

Published on: July 20, 2022

Related Concept Videos

Electron Transport Chain: Complex III and IV01:43

Electron Transport Chain: Complex III and IV

During the electron transport chain, electrons from NADH and FADH2 are first transferred to complexes I and II, respectively. These two complexes then transfer the electrons to ubiquinol, which carries them further to complex III. Complex III passes the electrons across the intermembrane space to Cyt c, which carries them further to complex IV. Complex IV donates electrons to oxygen and reduces it to water. As electrons pass through complexes I, III, and IV, the energy released aids the pumping...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...